Gabapentin Market Size, Share, Trends, Industry Analysis Report: By Dosage, Type, Method, Application, Distribution Channel, and Region

Description

List of Tables

The global gabapentin market size is expected to reach USD 3,768.43 million by 2034, according to a new study by Polaris Market Research. The report "Gabapentin Market Size, Share, Trends, Industry Analysis Report: By Dosage (Capsule and Tablet), Type, Method, Application, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Gabapentin is a prescription medication used to manage neuropathic pain, epilepsy, and restless legs syndrome by altering nerve signaling in the brain.

The gabapentin market is experiencing steady growth, driven by the increasing prevalence of neuropathic disorders, rising demand for cost-effective generic alternatives, and expanding applications beyond its approved indications. Opportunities in the market include the expansion of distribution channels, particularly through online and retail pharmacies, and the development of improved formulations for enhanced patient compliance.

Key gabapentin market trends include regulatory scrutiny due to potential misuse, growing off-label prescriptions, and strategic collaborations among pharmaceutical companies to strengthen market presence. Overall, the market is expected to expand as awareness of neuropathic conditions increases and demand for affordable treatment options rises.

Gabapentin Market Report Highlights

By dosage, the capsule segment held the largest market share due to their widespread prescription and patient preference for ease of administration. The tablet segment is witnessing notable growth as manufacturers introduce cost-effective generic alternatives.
Based on type, the generic segment held the largest share of the gabapentin market in 2024, led by formulations that offer a cost-effective alternative to branded versions.
In 2024, North America held the largest market share due to high prescription rates and established pharmaceutical infrastructure.
Asia Pacific is witnessing rapid growth, driven by expanding healthcare access and rising demand for cost-effective generic medications.
The gabapentin market features several key players actively involved in the development, manufacturing, and distribution of gabapentin formulations. A few players are Amneal Pharmaceuticals, Inc.; Apotex Inc.; Aurobindo Pharma Ltd.; Dr. Reddy's Laboratories Ltd.; Glenmark Pharmaceuticals Ltd.; Lupin Limited; Mylan N.V.; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.; and Torrent Pharmaceuticals Ltd.

Polaris Market Research has segmented the gabapentin market report on the basis of dosage, type, method, application, distribution channel, and region:

By Dosage Outlook (Revenue - USD Million, 2020-2034)

Capsule
Tablet

By Type Outlook (Revenue - USD Million, 2020-2034)

Branded
Generic

By Method Outlook (Revenue - USD Million, 2020-2034)

Column-Based
Magnetic Beads
Reagent-Based
Others

By Application Outlook (Revenue - USD Million, 2020-2034)

Neuropathic Pain
Epilepsy
Restless Legs Syndrome
Others

By Distribution Channel Outlook (Revenue - USD Million, 2020-2034)

Retail Pharmacy
Hospital Pharmacy
Online Pharmacy

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Netherlands
Russia
Rest of Europe
Asia Pacific
China
Japan
India
Malaysia
South Korea
Indonesia
Australia
Vietnam
Rest of Asia Pacific
Middle East & Africa
Saudi Arabia
UAE
Israel
South Africa
Rest of Middle East & Africa
Latin America
Mexico
Brazil
Argentina
Rest of Latin America

Product Code: PM3214

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global Gabapentin Market Insights

4.1. Gabapentin Market - Frequency Snapshot
4.2. Gabapentin Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Increasing Prevalence of Neuropathic Pain and Epilepsy
  - 4.2.1.2. Off-Label Use and Expanding Therapeutic Applications
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Lack of Awareness
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Gabapentin Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global Gabapentin Market, by Dosage

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global Gabapentin Market, by Dosage, 2020-2034 (USD Million)
5.3. Capsule
- 5.3.1. Global Gabapentin Market, Capsule, by Region, 2020-2034 (USD Million)
5.4. Tablet
- 5.4.1. Global Gabapentin Market, by Tablet, by Region, 2020-2034 (USD Million)

6. Global Gabapentin Market, by Type

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global Gabapentin Market, by Type, 2020-2034 (USD Million)
6.3. Branded
- 6.3.1. Global Gabapentin Market, by Branded, by Region, 2020-2034 (USD Million)
6.4. Generic
- 6.4.1. Global Gabapentin Market, by Generic, by Region, 2020-2034 (USD Million)

7. Global Gabapentin Market, by Method

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global Gabapentin Market, by Method, 2020-2034 (USD Million)
7.3. Column-based
- 7.3.1. Global Gabapentin Market, by Column-based, by Region, 2020-2034 (USD Million)
7.4. Magnetic Beads
- 7.4.1. Global Gabapentin Market, Magnetic Beads, by Region, 2020-2034 (USD Million)
7.5. Reagent-based
- 7.5.1. Global Gabapentin Market, Reagent-based, by Region, 2020-2034 (USD Million)
7.6. Others
- 7.6.1. Global Gabapentin Market, Others, by Region, 2020-2034 (USD Million)

8. Global Gabapentin Market, by Application

8.1. Key Findings
8.2. Introduction
- 8.2.1. Global Gabapentin Market, by Application, 2020-2034 (USD Million)
8.3. Neuropathic Pain
- 8.3.1. Global Gabapentin Market, by Neuropathic Pain, by Region, 2020-2034 (USD Million)
8.4. Epilepsy
- 8.4.1. Global Gabapentin Market, by Epilepsy, by Region, 2020-2034 (USD Million)
8.5. Restless Legs Syndrome
- 8.5.1. Global Gabapentin Market, by Restless Legs Syndrome, by Region, 2020-2034 (USD Million)
8.6. Others
- 8.6.1. Global Gabapentin Market, by Others, by Region, 2020-2034 (USD Million)

9. Global Gabapentin Market, by Distribution Channel

9.1. Key Findings
9.2. Introduction
- 9.2.1. Global Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
9.3. Retail Pharmacy
- 9.3.1. Global Gabapentin Market, by Retail Pharmacy, by Region, 2020-2034 (USD Million)
9.4. Hospital Pharmacy
- 9.4.1. Global Gabapentin Market, by Hospital Pharmacy, by Region, 2020-2034 (USD Million)
9.5. Online Pharmacy
- 9.5.1. Global Gabapentin Market, by Online Pharmacy, by Region, 2020-2034 (USD Million)

10. Global Gabapentin Market, by Geography

10.1. Key Findings
10.2. Introduction
- 10.2.1. Gabapentin Market Assessment, By Geography, 2020-2034 (USD Million)
10.3. Gabapentin Market - North America
- 10.3.1. North America: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
- 10.3.2. North America: Gabapentin Market, by Type, 2020-2034 (USD Million)
- 10.3.3. North America: Gabapentin Market, by Method, 2020-2034 (USD Million)
- 10.3.4. North America: Gabapentin Market, by Application, 2020-2034 (USD Million)
- 10.3.5. North America: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.3.7. Gabapentin Market - U.S.
  - 10.3.7.1. U.S.: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.3.7.2. U.S.: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.3.7.3. U.S.: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.3.7.4. U.S.: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.3.7.5. U.S.: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.3.8. Gabapentin Market - Canada
  - 10.3.8.1. Canada: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.3.8.2. Canada: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.3.8.3. Canada: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.3.8.4. Canada: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.3.8.5. Canada: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
10.4. Gabapentin Market - Europe
- 10.4.1. Europe: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
- 10.4.2. Europe: Gabapentin Market, by Type, 2020-2034 (USD Million)
- 10.4.3. Europe: Gabapentin Market, by Method, 2020-2034 (USD Million)
- 10.4.4. Europe: Gabapentin Market, by Application, 2020-2034 (USD Million)
- 10.4.5. Europe: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.4.6. Gabapentin Market - UK
  - 10.4.6.1. UK: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.4.6.2. UK: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.4.6.3. UK: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.4.6.4. UK: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.4.6.5. UK: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.4.7. Gabapentin Market - France
  - 10.4.7.1. France: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.4.7.2. France: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.4.7.3. France: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.4.7.4. France: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.4.7.5. France: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.4.8. Gabapentin Market - Germany
  - 10.4.8.1. Germany: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.4.8.2. Germany: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.4.8.3. Germany: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.4.8.4. Germany: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.4.8.5. Germany: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.4.9. Gabapentin Market - Italy
  - 10.4.9.1. Italy: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.4.9.2. Italy: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.4.9.3. Italy: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.4.9.4. Italy: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.4.9.5. Italy: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.4.10. Gabapentin Market - Spain
  - 10.4.10.1. Spain: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.4.10.2. Spain: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.4.10.3. Spain: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.4.10.4. Spain: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.4.10.5. Spain: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.4.11. Gabapentin Market - Netherlands
  - 10.4.11.1. Netherlands: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.4.11.2. Netherlands: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.4.11.3. Netherlands: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.4.11.4. Netherlands: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.4.11.5. Netherlands: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.4.12. Gabapentin Market - Russia
  - 10.4.12.1. Russia: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.4.12.2. Russia: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.4.12.3. Russia: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.4.12.4. Russia: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.4.12.5. Russia: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.4.13. Gabapentin Market - Rest of Europe
  - 10.4.13.1. Rest of Europe: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.4.13.2. Rest of Europe: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.4.13.3. Rest of Europe: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.4.13.4. Rest of Europe: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.4.13.5. Rest of Europe: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
10.5. Gabapentin Market - Asia Pacific
- 10.5.1. Asia Pacific: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
- 10.5.2. Asia Pacific: Gabapentin Market, by Type, 2020-2034 (USD Million)
- 10.5.3. Asia Pacific: Gabapentin Market, by Method, 2020-2034 (USD Million)
- 10.5.4. Asia Pacific: Gabapentin Market, by Application, 2020-2034 (USD Million)
- 10.5.5. Asia Pacific: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.5.6. Gabapentin Market - China
  - 10.5.6.1. China: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.5.6.2. China: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.5.6.3. China: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.5.6.4. China: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.5.6.5. China: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.5.7. Gabapentin Market - India
  - 10.5.7.1. India: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.5.7.2. India: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.5.7.3. India: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.5.7.4. India: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.5.7.5. India: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.5.8. Gabapentin Market - Malaysia
  - 10.5.8.1. Malaysia: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.5.8.2. Malaysia: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.5.8.3. Malaysia: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.5.8.4. Malaysia: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.5.8.5. Malaysia: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.5.9. Gabapentin Market - Japan
  - 10.5.9.1. Japan: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.5.9.2. Japan: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.5.9.3. Japan: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.5.9.4. Japan: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.5.9.5. Japan: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.5.10. Gabapentin Market - Indonesia
  - 10.5.10.1. Indonesia: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.5.10.2. Indonesia: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.5.10.3. Indonesia: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.5.10.4. Indonesia: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.5.10.5. Indonesia: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.5.11. Gabapentin Market - South Korea
  - 10.5.11.1. South Korea: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.5.11.2. South Korea: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.5.11.3. South Korea: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.5.11.4. South Korea: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.5.11.5. South Korea: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.5.12. Gabapentin Market - Australia
  - 10.5.12.1. Australia: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.5.12.2. Australia: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.5.12.3. Australia: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.5.12.4. Australia: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.5.12.5. Australia: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.5.13. Gabapentin Market - Rest of Asia Pacific
  - 10.5.13.1. Rest of Asia Pacific: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.5.13.2. Rest of Asia Pacific: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.5.13.3. Rest of Asia Pacific: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.5.13.4. Rest of Asia Pacific: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.5.13.5. Rest of Asia Pacific: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
10.6. Gabapentin Market - Middle East & Africa
- 10.6.1. Middle East & Africa: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
- 10.6.2. Middle East & Africa: Gabapentin Market, by Type, 2020-2034 (USD Million)
- 10.6.3. Middle East & Africa: Gabapentin Market, by Method, 2020-2034 (USD Million)
- 10.6.4. Middle East & Africa: Gabapentin Market, by Application, 2020-2034 (USD Million)
- 10.6.5. Middle East & Africa: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.6.6. Gabapentin Market - Saudi Arabia
  - 10.6.6.1. Saudi Arabia: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.6.6.2. Saudi Arabia: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.6.6.3. Saudi Arabia: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.6.6.4. Saudi Arabia: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.6.6.5. Saudi Arabia: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.6.7. Gabapentin Market - UAE
  - 10.6.7.1. UAE: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.6.7.2. UAE: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.6.7.3. UAE: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.6.7.4. UAE: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.6.7.5. UAE: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.6.8. Gabapentin Market - Israel
  - 10.6.8.1. Israel: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.6.8.2. Israel: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.6.8.3. Israel: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.6.8.4. Israel: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.6.8.5. Israel: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.6.9. Gabapentin Market - South Africa
  - 10.6.9.1. South Africa: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.6.9.2. South Africa: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.6.9.3. South Africa: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.6.9.4. South Africa: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.6.9.5. South Africa: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.6.10. Gabapentin Market - Rest of Middle East & Africa
  - 10.6.10.1. Rest of Middle East & Africa: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.6.10.2. Rest of Middle East & Africa: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.6.10.3. Rest of Middle East & Africa: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.6.10.4. Rest of Middle East & Africa: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.6.10.5. Rest of Middle East & Africa: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
10.7. Gabapentin Market - Latin America
- 10.7.1. Latin America: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
- 10.7.2. Latin America: Gabapentin Market, by Type, 2020-2034 (USD Million)
- 10.7.3. Latin America: Gabapentin Market, by Method, 2020-2034 (USD Million)
- 10.7.4. Latin America: Gabapentin Market, by Application, 2020-2034 (USD Million)
- 10.7.5. Latin America: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.7.6. Gabapentin Market - Mexico
  - 10.7.6.1. Mexico: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.7.6.2. Mexico: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.7.6.3. Mexico: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.7.6.4. Mexico: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.7.6.5. Mexico: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.7.7. Gabapentin Market - Brazil
  - 10.7.7.1. Brazil: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.7.7.2. Brazil: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.7.7.3. Brazil: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.7.7.4. Brazil: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.7.7.5. Brazil: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.7.8. Gabapentin Market - Argentina
  - 10.7.8.1. Argentina: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.7.8.2. Argentina: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.7.8.3. Argentina: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.7.8.4. Argentina: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.7.8.5. Argentina: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)
- 10.7.9. Gabapentin Market - Rest of Latin America
  - 10.7.9.1. Rest of Latin America: Gabapentin Market, by Dosage, 2020-2034 (USD Million)
  - 10.7.9.2. Rest of Latin America: Gabapentin Market, by Type, 2020-2034 (USD Million)
  - 10.7.9.3. Rest of Latin America: Gabapentin Market, by Method, 2020-2034 (USD Million)
  - 10.7.9.4. Rest of Latin America: Gabapentin Market, by Application, 2020-2034 (USD Million)
  - 10.7.9.5. Rest of Latin America: Gabapentin Market, by Distribution Channel, 2020-2034 (USD Million)

11. Competitive Landscape

11.1. Expansion and Acquisition Analysis
- 11.1.1. Expansion
- 11.1.2. Acquisitions
11.2. Partnerships/Collaborations/Agreements/Exhibitions

12. Company Profiles

12.1. Amneal Pharmaceuticals, Inc.
- 12.1.1. Company Overview
- 12.1.2. Financial Performance
- 12.1.3. Product Benchmarking
- 12.1.4. Recent Development
12.2. Apotex Inc.
- 12.2.1. Company Overview
- 12.2.2. Financial Performance
- 12.2.3. Product Benchmarking
- 12.2.4. Recent Development
12.3. Aurobindo Pharma Ltd.
- 12.3.1. Company Overview
- 12.3.2. Financial Performance
- 12.3.3. Product Benchmarking
- 12.3.4. Recent Development
12.4. Dr. Reddy's Laboratories Ltd.
- 12.4.1. Company Overview
- 12.4.2. Financial Performance
- 12.4.3. Product Benchmarking
- 12.4.4. Recent Development
12.5. Glenmark Pharmaceuticals Ltd.
- 12.5.1. Company Overview
- 12.5.2. Financial Performance
- 12.5.3. Product Benchmarking
- 12.5.4. Recent Development
12.6. Hikma Pharmaceuticals PLC
- 12.6.1. Company Overview
- 12.6.2. Financial Performance
- 12.6.3. Product Benchmarking
- 12.6.4. Recent Development
12.7. Lupin Limited
- 12.7.1. Company Overview
- 12.7.2. Financial Performance
- 12.7.3. Product Benchmarking
- 12.7.4. Recent Development
12.8. Mylan N.V.
- 12.8.1. Company Overview
- 12.8.2. Financial Performance
- 12.8.3. Product Benchmarking
- 12.8.4. Recent Development
12.9. Novartis AG
- 12.9.1. Company Overview
- 12.9.2. Financial Performance
- 12.9.3. Product Benchmarking
- 12.9.4. Recent Development
12.10. Pfizer Inc.
- 12.10.1. Company Overview
- 12.10.2. Financial Performance
- 12.10.3. Product Benchmarking
- 12.10.4. Recent Development